Terumo (OTCMKTS:TRUMY) Stock Price Up 9.4% – Here’s Why

Terumo Corp. (OTCMKTS:TRUMY) shot up 9.4% on Thursday. The stock traded as high as $16.4950 and last traded at $16.4622. 3,217 shares traded hands during trading, a decline of 99% from the average daily volume of 238,558 shares. The stock had previously closed at $15.05.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TRUMY shares. Nomura raised Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Zacks Research raised shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, Terumo currently has a consensus rating of “Strong Buy”.

Terumo Price Performance

The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $23.45 billion, a P/E ratio of 22.39 and a beta of 0.82. The business’s fifty day moving average price is $14.82 and its 200-day moving average price is $14.04.

Terumo (OTCMKTS:TRUMY) last issued its earnings results on Friday, August 7th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.13. The company had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. As a group, sell-side analysts predict that Terumo Corp. will post 0.86 earnings per share for the current fiscal year.

About Terumo

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.

The company’s products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.